Company History

Bebaas is a California corporation founded in June, 2004 and based in Newport Beach, California. Bebaas is a biopharmaceutical company focused on the discovery, development, and commercialization of novel drug therapies utilizing its patent-pending cobalamin delivery mechanism. The Company's research has led to the first-ever drug product capable of getting as much cobalamin, vitamin B12, into the bloodstream as an intramuscular injection of vitamin B12, and it maintains those levels longer than the injections. Additionally, it allows for cobalamin to be utilized as either a scavenger or a donor, leaving the door open to virtually limitless drug discovery. Bebaas is developing an internal product pipeline and lead compounds through the application of its proprietary cobalamin delivery technology. The Company’s drug discovery platform, which has been validated in animal models, is based on the utilization of its patent-pending combinations of various vitamin B12 analogs that generate extremely high cobalamin levels. Numerous API can be added to the cobalamin delivery for oncology, hematology, cardiology, cyanide toxicity, wound healing and other therapeutic applications. The basis for the research platform has led to the Company’s creation of the first completely non-invasive treatment for pernicious anemia, a cherry-flavored sublingual lozenge, CobacanTM, that has demonstrated in animal models to deliver a far more potent dose than the current standard of care, intramuscular injections of cobalamin.

2901 West Coast Highway, Suite 200, Newport Beach, California, 92663

site created by Dan Bremenstuhl